Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab long-term safety in palmoplantar pustulosis
NCT04493424Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2020
- Primary completion
- Jan 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 2 trial of spesolimab in palmoplantar pustulosis (PPP), sponsored by Boehringer Ingelheim. Started Sep 2020; status: terminated.
02
Drugs
spesolimab
03
Conditions
palmoplantar pustulosis (PPP)
Beyond the preview
Go deeper on NCT04493424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04493424.